Skip to content
value.today

Diffusion Pharmaceuticals LLC

Total raised
$18 M
5 rounds on record
Latest round
$2 M
Dec 2015
First round on record
Jul 2009
Today
Private
No later event on record

Funding rounds

5 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Diffusion Pharmaceuticals LLC
MonthRaisedRaiseSizeInvestorsSoldFiling
Dec 2015$2 MNo. 5$2 to $10 million

Diffusion Pharmaceuticals LLC: Raise no. 5, Dec 2015

Investors in this round

28 investors had bought by the notice of Dec 22, 2015: 28 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $5 M offered; $3 M still to sell
Smallest investment taken
$5,000
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them, other: Each convertible note bears interest of 1.0% for four years and is convertible into membership units of the issuer at a conversion price of $2.00 per unit.
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Limited Liability Company, incorporated in Virginia

People named in the notice

  • Ben L. Shealy · Executive Officer
  • David G. Kalergis · Executive Officer, Director
  • David R. Jones · Executive Officer
  • John L. Gainer · Executive Officer, Director
  • Alan R. Levin · Director
  • Mark T. Giles · Director
  • Robert W. Adams · Director
  • Thomas E. Byrne · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “In the ordinary course of business, the issuer may use some of the proceeds of the offering to pay salaries to certain of its executive officers and directors.”

Signed by Ben L. Shealy, Senior Vice President - Finance and Treasurer. Source: SEC Form D, newest notice filed Dec 22, 2015. Read the notice at the SEC.

debt, optionsSEC
Jun 2014$3 MNo. 4$2 to $10 million

Diffusion Pharmaceuticals LLC: Raise no. 4, Jun 2014

Investors in this round

30 investors had bought by the notice of Sep 4, 2014: 30 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$3 M of $3 M offered
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them, other: Each convertible note bears interest of 1.0% for four years and is convertible into membership units of the Company at a conversion price of $1.50 per unit.
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Limited Liability Company, incorporated in Virginia

People named in the notice

  • Ben L. Shealy · Executive Officer
  • David G. Kalergis · Executive Officer, Director
  • David R. Jones · Executive Officer
  • John L. Gainer · Executive Officer, Director
  • Mark T. Giles · Director
  • Robert W. Adams · Director
  • Thomas E. Byrne · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “In the ordinary course of business, the issuer may use some of the proceeds of the offering to pay salaries to certain of its executive officers and directors.”

Signed by Ben L. Shealy, Chief Financial Officer. Source: SEC Form D, newest notice filed Sep 4, 2014. Read the notice at the SEC.

debt, optionsSEC
May 2013$5 MNo. 3$2 to $10 million

Diffusion Pharmaceuticals LLC: Raise no. 3, May 2013

Investors in this round

19 investors had bought by the notice of Jun 21, 2013: 19 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$5 M of $5 M offered
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them, other: Each convertible note bears interest of 1.0% for four years and is convertible into membership units of the Company at a conversion price of $1.25 per unit.
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Limited Liability Company, incorporated in Virginia

People named in the notice

  • Ben L. Shealy · Executive Officer
  • David G. Kalergis · Executive Officer, Director
  • John L. Gainer · Executive Officer, Director
  • Kim L. Whitten · Executive Officer
  • Mark T. GIles · Director
  • Robert W. Adams · Director
  • Thomas E. Byrne · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “In the ordinary course of business, the issuer may use some of the proceeds of the offering to pay salaries to certain of its executive officers and directors.”

Signed by Ben L. Shealy, Chief Financial Officer and Treasurer. Source: SEC Form D, newest notice filed Jun 21, 2013. Read the notice at the SEC.

debt, optionsSEC
Sep 2012$5 MNo. 2$2 to $10 million

Diffusion Pharmaceuticals LLC: Raise no. 2, Sep 2012

Investors in this round

34 investors had bought by the notice of Oct 1, 2012: 34 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$5 M of $6 M offered; $1 M still to sell
Smallest investment taken
$5,000
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them, other: Each convertible note bears interest of 1.0% for four years and is convertible into membership units of the Company at a conversion price of $1.00 per unit.
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Limited Liability Company, incorporated in Virginia

People named in the notice

  • Ben L. Shealy · Executive Officer
  • David G. Kalergis · Executive Officer, Director
  • John L. Gainer · Executive Officer, Director
  • Kim L. Whitten · Executive Officer
  • Matthew W. Hantzmon · Executive Officer
  • Mark T. Giles · Director
  • Robert W. Adams · Director
  • Thomas E. Byrne · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “In the ordinary course of business, the issuer may use some of the proceeds of the offering to pay salaries to certain of its executive officers and directors.”

Signed by Ben L. Shealy, Chief Financial Officer and Treasurer. Source: SEC Form D, newest notice filed Oct 1, 2012. Read the notice at the SEC.

debt, optionsSEC
Jul 2009$2 MNo. 1Under $2 million

Diffusion Pharmaceuticals LLC: Raise no. 1, Jul 2009

Investors in this round

14 investors had bought by the notice of Aug 26, 2009: 14 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $5 M offered; $3 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
$425,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Limited Liability Company, incorporated in Virginia

People named in the notice

  • Ben L. Shealy · Executive Officer
  • David Kalergis · Executive Officer, Director
  • Matthew Hantzmon · Executive Officer
  • Thomas E. Byrne · Executive Officer, Director
  • John L. Gainer · Director
  • Mark T. Giles · Director
  • Robert W. Adams · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by David G. Kalergis, Chief Executive Officer. Source: SEC Form D, newest notice filed Aug 26, 2009. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Diffusion Pharmaceuticals LLC chose not to state its revenue in its newest notice of a funding round (Dec 2015).

    SEC Form D · Dec 2015

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Dec 2015

That is all the official record says: Diffusion Pharmaceuticals LLC has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Diffusion Pharmaceuticals LLC is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 5 rounds above had up to 34 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Diffusion Pharmaceuticals LLC
NameRoleNamed in
Ben L. ShealyExecutive officerDec 2015
David G. KalergisExecutive officerDec 2015
David R. JonesExecutive officerDec 2015
John L. GainerExecutive officerDec 2015
Kim L. WhittenExecutive officerJun 2013
Matthew W. HantzmonExecutive officerOct 2012
David KalergisExecutive officerAug 2009
Matthew HantzmonExecutive officerAug 2009
Thomas E. ByrneExecutive officerAug 2009
Alan R. LevinDirectorDec 2015
David G. KalergisDirectorDec 2015
John L. GainerDirectorDec 2015
Mark T. GilesDirectorDec 2015
Robert W. AdamsDirectorDec 2015
Thomas E. ByrneDirectorDec 2015
Mark T. GIlesDirectorJun 2013
David KalergisDirectorAug 2009